{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T13:57:36Z","timestamp":1692626256206},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11899-008-0019-5","type":"journal-article","created":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T23:31:03Z","timestamp":1223595063000},"page":"126-131","source":"Crossref","is-referenced-by-count":3,"title":["Nodular lymphocyte-predominant Hodgkin lymphoma"],"prefix":"10.1007","volume":"3","author":[{"given":"Michael","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Nogov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,10]]},"reference":[{"issue":"Suppl1","key":"19_CR1","doi-asserted-by":"crossref","first-page":"i54","DOI":"10.1093\/annonc\/mdi814","volume":"16","author":"L.M. Jost","year":"2005","unstructured":"Jost LM, Stahel RA: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin\u2019s disease. Ann Oncol 2005, 16(Suppl 1):i54\u2013i55.","journal-title":"Ann Oncol"},{"key":"19_CR2","volume-title":"SEER Cancer Statistics Review: 1973\u20131994","author":"L.A. Ries","year":"1997","unstructured":"Ries LA, Kosary CL, Hankey BF, et al.: SEER Cancer Statistics Review: 1973\u20131994. Bethesda, MD: National Cancer Institute; 1997."},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","volume":"17","author":"V. Diehl","year":"1999","unstructured":"Diehl V, Sextro M, Franklin J, et al.: Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease. J Clin Oncol 1999, 17:776\u2013783.","journal-title":"J Clin Oncol"},{"key":"19_CR4","first-page":"1889","volume":"96","author":"I. Anagnostopoulos","year":"2000","unstructured":"Anagnostopoulos I, Hansmann ML, Franssila K, et al.: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000, 96:1889\u20131899.","journal-title":"Blood"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/1097-0142(19870101)59:1<99::AID-CNCR2820590122>3.0.CO;2-J","volume":"59","author":"M.A. Trudel","year":"1987","unstructured":"Trudel MA, Krikorian JG, Neiman RS: Lymphocyte predominance Hodgkin\u2019s disease. A clinicopathologic reassessment. Cancer 1987, 59:99\u2013106.","journal-title":"Cancer"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a059244","volume":"6","author":"V.I. Pappa","year":"1995","unstructured":"Pappa VI, Norton AJ, Gupta RK, et al.: Nodular type of lymphocyte predominant Hodgkin\u2019s disease. A clinical study of 50 cases. Ann Oncol 1995, 6:559\u2013565.","journal-title":"Ann Oncol"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","volume":"16","author":"L. Nogov\u00e1","year":"2005","unstructured":"Nogov\u00e1 L, Reineke T, Eich HT, et al.: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005, 16:1683\u20131687.","journal-title":"Ann Oncol"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","volume":"101","author":"B.C. Ekstrand","year":"2003","unstructured":"Ekstrand BC, Lucas JB, Horwitz SM, et al.: Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003, 101:4285\u20134289.","journal-title":"Blood"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","volume":"21","author":"B. Pellegrino","year":"2003","unstructured":"Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al.: Lymphocyte-predominant Hodgkin\u2019s lymphoma in children: therapeutic abstention after initial lymph node resection\u2014a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003, 21:2948\u20132952.","journal-title":"J Clin Oncol"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","volume":"110","author":"C. Mauz-K\u00f6rholz","year":"2007","unstructured":"Mauz-K\u00f6rholz C, Gorde-Grosjean S, Hasenclever D, et al.: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007, 110:179\u2013185.","journal-title":"Cancer"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00000478-198404000-00002","volume":"8","author":"B.F. Burns","year":"1984","unstructured":"Burns BF, Colby TV, Dorfman RF: Differential diagnostic features of nodular L & H Hodgkin\u2019s disease, including progressive transformation of germinal centers. Am J Surg Pathol 1984, 8:253\u2013261.","journal-title":"Am J Surg Pathol"},{"key":"19_CR12","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW, eds.: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2559.1990.tb01084.x","volume":"16","author":"D.S. Nicholas","year":"1990","unstructured":"Nicholas DS, Harris S, Wright DH: Lymphocyte predominance Hodgkin\u2019s disease\u2014an immunohistochemical study. Histopathology 1990, 16:157\u2013165.","journal-title":"Histopathology"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1073\/pnas.94.17.9337","volume":"94","author":"A. Bracuninger","year":"1997","unstructured":"Bracuninger A, Kuppers R, Strickler JG, et al.: Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A. 1997, 94:9337\u20139342.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2003-05-1487","volume":"103","author":"T. Marafioti","year":"2004","unstructured":"Marafioti T, Pozzobon M, Hansmann ML, et al.: Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004, 103:188\u2013193.","journal-title":"Blood"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.V86.6.2312.bloodjournal8662312","volume":"86","author":"R.S. Wickert","year":"1995","unstructured":"Wickert RS, Weisenburger DD, Tierens A, et al.: Clonal relationship between lymphocytic predominance Hodgkin\u2019s disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 1995, 86:2312\u20132320.","journal-title":"Blood"},{"issue":"Suppl2","key":"19_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/annonc\/2.suppl_2.83","volume":"2","author":"M.H. Bennett","year":"1991","unstructured":"Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B: Non-Hodgkin\u2019s lymphoma arising in patients treated for Hodgkin\u2019s disease in the BNLI: a 20-year experience British. National Lymphoma Investigation. Ann Oncol 1991, 2(Suppl 2):83\u201392.","journal-title":"Ann Oncol"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1080\/1042819031000123528","volume":"44","author":"J.Z. Huang","year":"2003","unstructured":"Huang JZ, Weisenburger DD, Vose JM, et al.: Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2003, 44:1903\u20131910.","journal-title":"Leuk Lymphoma"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","volume":"26","author":"L. Nogov\u00e1","year":"2008","unstructured":"Nogov\u00e1 L, Reineke T, Brillant C, et al.: Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008, 26:434\u2013439.","journal-title":"J Clin Oncol"},{"key":"19_CR20","doi-asserted-by":"crossref","unstructured":"Nogov\u00e1 L, Reineke T, Josting A, et al.: Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma\u2014comparison of outcomes. Eur J Haematol Suppl 2005, Jul:106\u2013110.","DOI":"10.1111\/j.1600-0609.2005.00462.x"},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","volume":"104","author":"A. Wirth","year":"2005","unstructured":"Wirth A, Yuen K, Barton M, et al.: Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005, 104:1221\u20131229.","journal-title":"Cancer"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/COC.0b013e318145b9db","volume":"30","author":"B.S. Chera","year":"2007","unstructured":"Chera BS, Olivier K, Morris CG, et al.: Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida. Am J Clin Oncol 2007, 30:601\u2013606.","journal-title":"Am J Clin Oncol"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","volume":"8","author":"P.J. Schlembach","year":"2002","unstructured":"Schlembach PJ, Wilder RB, Jones D, et al.: Radiotherapy alone for lymphocyte-predominant Hodgkin\u2019s disease. Cancer J 2002, 8:377\u2013383.","journal-title":"Cancer J"},{"issue":"Suppl4","key":"19_CR24","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S0959-8049(01)00446-4","volume":"38","author":"J. Raemaekers","year":"2002","unstructured":"Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al.: The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002, 38(Suppl 4):S107\u2013S113.","journal-title":"Eur J Cancer"},{"issue":"Suppl5","key":"19_CR25","first-page":"C012","volume":"92","author":"K.J. Savage","year":"2007","unstructured":"Savage KJ, Hoskins P, Klasa R, et al.: ABVD chemotherapy is essential for optimal treatment of limited stage nodular lymphocyte predominant Hodgkin Lymphoma. Haematologica 2007, 92(Suppl 5):C012.","journal-title":"Haematologica"},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","volume":"111","author":"H. Schulz","year":"2008","unstructured":"Schulz H, Rehwald U, Morschhauser F, et al.: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008, 111:109\u2013111.","journal-title":"Blood"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","volume":"101","author":"U. Rehwald","year":"2003","unstructured":"Rehwald U, Schulz H, Reiser M, et al.: Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003, 101:420\u2013424.","journal-title":"Blood"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1200\/JCO.2005.17.970","volume":"23","author":"A. Shimabukuro-Vornhagen","year":"2005","unstructured":"Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al.: Lymphocyte-rich classical Hodgkin\u2019s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin\u2019s Study Group trials. J Clin Oncol 2005, 23:5739\u20135745.","journal-title":"J Clin Oncol"},{"key":"19_CR29","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"P. Feugier","year":"2004","unstructured":"Feugier P, Labouyrie E, Djeridane M, et al.: Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 2004, 104:2675\u20132681.","journal-title":"Blood"},{"issue":"Suppl5","key":"19_CR30","first-page":"P077","volume":"92","author":"M.A. Fanale","year":"2007","unstructured":"Fanale MA, Fayad LE, Romaguera JE, et al.: Experience with R-CHOP in patients with lymphocyte predominant Hodgkin Lymphoma (LPHL). Haematologica 2007, 92(Suppl 5):P077.","journal-title":"Haematologica"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0019-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-008-0019-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0019-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T01:42:57Z","timestamp":1588988577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-008-0019-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s11899-008-0019-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}